N/A N=20 Promoting Health Through Parent Empowerment and the Activation of Routines (PrO-PEAR)
Down Syndrome
Primary: Number of Pro-PEAR Intervention Sessions Completed — 9.1 # of sessions completed
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=274 A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
BRAF V600E Mutation Positive · Metastatic Colorectal Cancer
Primary: Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients — 17; 6; 10; 1 Participants
N/A N=7 Assessing Variability of the Ventilatory Response to Duffin's Rebreathing Procedure
Ventilation · Reproducibility · Physiology
Primary: Baseline Minute Ventilation — 11.6; 12.0 L/min
Phase 1 N=22 Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers
Healthy Volunteers
Primary: Percentage of Dose Excreted in Urine - MB Cohort — 3.81 Percentage
N/A N=120 Improving Function Through Primary Care Treatment of Posttraumatic Stress Disorder (PTSD)
Posttraumatic Stress Disorder
Primary: World Health Organization Disability Assessment Scale 2.0 Change — -7.5; -4.3 units on a scale — p=0.33
N/A N=85 A Randomized Controlled Trial of an Exposure-Based Treatment for Perfectionism
Perfectionism
Primary: Frost Multidimensional Perfectionism Scale (FMPS)- Concern Over Mistakes Subscale — 34.00; 35.71; 34.53; 32.34 units on a scale
N/A N=900 Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
Diabetic Retinopathy · Diabetic Eye Problems · Diabetic Macular Edema
Primary: Sensitivity(mtmDR) — 90.48; 95.65; 95.19 percentage of true positives
N/A N=220,306 Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program
Proton Pump Inhibitors
Primary: PPI Prescribing (H1) — 73.69; 72.66 percentage of days on PPI
Phase 2 N=248 Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 62.2; 65.1; 50.6 percentage of participants
N/A N=9 Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals
HIV
Primary: Global Transcriptome Analysis — 116; 135 genes
N/A N=103 An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment
Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor · Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor · Haemophilia A
Primary: Mean Number of Daily Active Minutes of Physical Activity Performed by Participants (by Age Categories: 12-17, 18-30, and 31-50 Years) Over the Course of the Study…
Phase 4 N=23 Anesthesia and Postoperative Pain
Postoperative Pain
Primary: Score on a Pain Rating Scale (Numerical Analog Score) — 1.5; 4.9 scores on a scale
N/A N=58 The Accuracy of Flap Thickness Versus the Pre-determined Surgical Planning Using WaveLight® FS200
Myopia
Primary: The Resultant Thickness of the FS200 Created LASIK Flap Compared to Plan at the Surgical Visit. — 0.64 um
Phase 4 N=1,316 Improving Quitline Support Study
Tobacco Use Cessation
Primary: 7-Day Point-Prevalence Abstinence — 11; 7; 8; 10 Participants
Phase 3 N=56 Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Chronic Myelogenous Leukemia - Chronic Phase
Primary: Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A and B up to 24 Weeks — 23; 26; 1; 3 Participants